Consequently, the 2017 European Leukemia Network recommended a risk classification system that integrates both cytogenetic and molecular profiles of AML patients, considering the mutational status of FLT3‐ITD, NPM1, CEBPA, and TP53 [40]. This evidence concerns the gene NPM1 and acute myeloid leukemia.